Atopic Dermatitis

The seborrheic dermatitis market has been projected to grow through 2032, according to a new report from Delveinsight.

The expansion in market size coincides with the CAGR study, according to a press release. The report notes the recent approval of roflumilast foam 0.3% (ZORYVE, Arcutis) for treatin...

Key Takeaways

• 13 lipid-related metabolites show a causal relationship with atopic dermatitis risk, including specific cholesterol and triglyceride levels.
• A higher ratio linoleic acid to total fatty acids was protective against AD.

A two-sample Mendelian randomization (TSMR) study has identified 13 lipid-related metabolite traits that influence the risk of developing atopic dermatitis (AD).

Researchers examined genome-wide assoc...

Key Takeaways

• The moisturizer inhibited the growth of Staphylococcus aureus in vitro and promoted the proliferation of Staphylococcus epidermidis.

• Researchers point to potential applications in managing skin microbiota imbalances, particularly in the setting of AD.

A new in vitro study suggests a moisturizer containing colloidal oatmeal, patented filaggrin technology, niacinamide, and tocopheryl acetate selectively inhibits the growth and adhesion of Staphylococ...

Key Takeaways

• APG990's mechanism of action targets IL-13-driven inflammation, offering promise for conditions like atopic dermatitis.
• APG990 demonstrated a half-life of approximately 60 days, supporting extended dosing intervals up to six months.
• No serious adverse events were reported.

Apogee Therapeutics has reported positive interim results from a Phase 1 trial evaluating APG990, a subcutaneous, extended half-life monoclonal antibody targeting OX40L, for inflammatory and immunolog...

Key Takeaways

• The trial met its primary endpoint as well as its secondar endpoints.

• 25.4% of children treated with roflumilast cream 0.05% achieved vIGA-AD success at Week 4, compared to 10.7% with vehicle.

• Roflumilast cream 0.05% had a safety profile comparable to that seen in previous studies....

Arcutis Biotherapeutics announced today that the INTEGUMENT-PED Phase 3 trial had met its primary endpoint, according to a release from the manufacturer.

Researchers on the study evaluated the efficac...

Key Takeaways 

• Dupilumab achieved clinical remission in 33.1% of pediatric patients with moderate-to-severe atopic dermatitis, with sustained benefits observed off-treatment for up to six months.
• More than half of patients who achieved remission sustained it for at least three months after disconti...

A new study highlights the potential of dupilumab to deliver sustained remission in children with moderate-to-severe atopic dermatitis (AD).

The findings, presented as a poster at the 2025 Masterclass...

New research suggests a petrolatum and panthenol-based ointment (HO) was as effective as 0.1% triamcinolone acetonide in urea cream (TAU) in reducing the severity of mild-to-moderate chronic hand eczema (CHE).

Researchers included 30 patients with mild-to-moderate CHE who applied HO to one hand and ...

Key Takeaways

• Haptic feedback from an AI-powered device reduced nocturnal scratch events and duration in patients with atopic dermatitis.
• The devices showed efficacy without affecting sleep quality, and no adverse events were reported. 

A wearable sensor utilizing artificial intelligence (AI) with haptic feedback significantly reduced nocturnal scratching in adults with mild atopic dermatitis, a new study reports.

Researchers for the...

Key Takeaways

• The DELTA TEEN trial met its primary endpoint of improving symptoms of moderate to severe chronic hand eczema (CHE) in adolescents.
• The manufacturer said that this represents the fifth phase 3 success for Anzupgo, reinforcing its efficacy and safety profile.
• There are no currently app...

Phase 3 data from the DELTA TEEN trial demonstrated that Anzupgo® (delgocitinib) cream achieved significant improvements in symptoms of moderate to severe chronic hand eczema (CHE) in adolescents aged...